Skip to menu Skip to content Skip to footer

2024

Conference Publication

VIOLET: visual analytics for explainable quantum neural networks

Ruan, Shaolun, Liang, Zhiding, Guan, Qiang, Griffin, Paul, Wen, Xiaolin, Lin, Yanna and Wang, Yong (2024). VIOLET: visual analytics for explainable quantum neural networks. IEEE Pacific Visualization Conference 2024, Tokyo, Japan, 23-26 April 2024. Los Alamitos, CA USA: Institute of Electrical and Electronics Engineers. doi: 10.1109/tvcg.2024.3388557

VIOLET: visual analytics for explainable quantum neural networks

2019

Conference Publication

Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial

Lickliter, Jason D., Griffin, Paul, Vincent, Emmanuelle, Schuler, Armin, Harrison-Moench, Eleanor, Stahl, Michael, El Bawab, Samer, Kanceva, Radmila and Gascon, Pere (2019). Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31May - 4 June, 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.e14514

Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial

2019

Conference Publication

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

Collins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. 71st Annual Meeting of the American Academy of Neurology (AAN), Philadelphia, PA, United States, 4-10 May, 2019. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

2019

Conference Publication

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

Collins, Jon, Jones, Lori, Snyder, Michele, Sicard, Eric, Griffin, Paul, Webster, Lindsey, Fong, Regan, Coquery, Christine and Piscitelli, Stephen (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration. AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p5.2-079

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

2018

Conference Publication

A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer

Yamada, M., Miller, D., Lowe, M., Rowe, C., Wood, D., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J., Brandt, G., Griffin, P., Spleman, L. and Prow, T. (2018). A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer. International Investigative Dermatology (IID) Meeting, Orlando, FL, United States, 16-19 May 2018. New York, United States: Elsevier.

A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer

2016

Conference Publication

First-in-human phase 1 safety study of BLZ-100 in subjects with skin cancer

Spelman, L., Johnston, J., Prow, T., Yamada, M., Griffin, P., Wood, D. and Miller, D. (2016). First-in-human phase 1 safety study of BLZ-100 in subjects with skin cancer. Australasian College of Dermatologists 49th Annual Scientific Meeting, Perth, Australia, 14–17 May 2016. HOBOKEN: WILEY-BLACKWELL.

First-in-human phase 1 safety study of BLZ-100 in subjects with skin cancer

2014

Conference Publication

A phase 1 evaluation of the pharmacokinetic/pharmacodynamics interaction of the antimalarial agent KAE609 and piperaquine (PPQ)

Stein, Daniel, Jain, Jay Prakash, Lickliter, Jason, Kangas, Michael, Machineri, Surendra and Griffin, Paul (2014). A phase 1 evaluation of the pharmacokinetic/pharmacodynamics interaction of the antimalarial agent KAE609 and piperaquine (PPQ). Challanges in malaria research: Core science and innovation, Oxford, United Kingdom, 22-24 September 2014. London, United Kingdom: BioMed Central. doi: 10.1186/1475-2875-13-S1-P85

A phase 1 evaluation of the pharmacokinetic/pharmacodynamics interaction of the antimalarial agent KAE609 and piperaquine (PPQ)

2013

Conference Publication

Rapid Identification of Vancomycin Resistant Enterococci with Maldi-Tof Mass Spectrometry

Griffin, Paul, Price, Gareth, Hamilton, Brett, Schooneveldt, Jacqueline, Urbanski, Tess, Schlebusch, Sanmarie and Venter, Deon (2013). Rapid Identification of Vancomycin Resistant Enterococci with Maldi-Tof Mass Spectrometry. The Royal Australasian College of Physicians Future Directions in Health Congress 2013 (RACP), Perth, WA Australia, 26-29 May 2013. Richmond, VIC Australia: Wiley-Blackwell. doi: 10.1111/imj.12153

Rapid Identification of Vancomycin Resistant Enterococci with Maldi-Tof Mass Spectrometry

2013

Conference Publication

Rapid identification of VRE with MALDI-TOF MS

Griffin, Paul M., Price, Gareth R., Schooneveldt, Jacqueline M., Schlebusch, Sanmarié, Urbanski, Tess, Hamilton, Brett and Venter, Deon (2013). Rapid identification of VRE with MALDI-TOF MS. Australasian Division of the International Academy of Pathology 37th Annual Scientific Meeting 2012, Sydney, NSW Australia, 1-3 June 2012. London, United Kingdom: Elsevier. doi: 10.1097/01.pat.0000426852.32930.4a

Rapid identification of VRE with MALDI-TOF MS